SCHERING-PLOUGH INTERLEUKIN-4 PHASE II/III STUDIES PLANNED FOR NON-SMALL CELL LUNG CANCER, CEO LUCIANO SAYS; LEUCOMAX OUTLOOK NOT OPTIMISTIC
Executive Summary
Schering-Plough plans to begin Phase II/III trials of interleukin-4 in advanced non-small cell lung cancer later this year, Schering-Plough Chairman Robert Luciano told a June 30 meeting of securities analysts in New York City.